MGFA has partnered with Bionews to feature the “Myasthenia Gravis News” feed on our MGFA website. We are excited to offer the MG Community this insightful and informative news feed that covers many aspects of living with myasthenia – from research and study results to managing MG, helpful tips, and important news from across the MG World.
Myasthenia Gravis News is a digital platform intended to provide the myasthenia gravis (MG) community with the most recent news and information on MG, as well as first-hand community perspectives from patient and caregiver columnists. All articles on Myasthenia Gravis News are original content produced by in-house writers and editors. Occasionally, BioNews seeks the opinion of outside experts for interviews and Q&As.
Myasthenia Gravis News – The Web’s Daily Resource for Myasthenia Gravis News
- Myasthenia gravis gave me something unexpected: A loud voiceby Bionews Staff on June 27, 2025 at 12:00 pm
This is Jennifer Crow’s story: When I was first diagnosed with myasthenia gravis (MG), I thought having a name for my condition would unlock care and put me on the The post Myasthenia gravis gave me something unexpected: A loud voice appeared first on Myasthenia Gravis News.
- The weight of asking for help; the difference an act of service makesby Sarah Bendiff on June 26, 2025 at 2:00 pm
Algerian people are known for their oversized pride and ego. Asking for help — whether it’s about health or financial struggles — is often seen as shameful in our country, The post The weight of asking for help; the difference an act of service makes appeared first on Myasthenia Gravis News.
- How the ‘Bob’s Burgers’ family helps me find humor, hopeby Mark Harrington on June 25, 2025 at 2:00 pm
Living with myasthenia gravis (MG) means living with a body that doesn’t always cooperate. Muscle weakness, fatigue, and frustration can be daily companions. The support and love of family and The post How the ‘Bob’s Burgers’ family helps me find humor, hope appeared first on Myasthenia Gravis News.
- Telitacicept named orphan drug in EU as MG therapyby Michela Luciano, PhD on June 25, 2025 at 1:45 pm
Telitacicept, a B-cell-targeting therapy for myasthenia gravis (MG), has been granted orphan drug status in the European Union, according to its developer Remegen. Orphan drug designation, or ODD, is awarded The post Telitacicept named orphan drug in EU as MG therapy appeared first on Myasthenia Gravis News.
- Together, facing the challenge of a myasthenia gravis diagnosisby Bionews Staff on June 25, 2025 at 12:00 pm
Note: Mohammed Hanafi’s girlfriend Sarah Bendiff is a Myasthenia Gravis News columnist who writes about her journey with MG. This is Mohammed Hanafi’s story: At the beginning of our relationship, The post Together, facing the challenge of a myasthenia gravis diagnosis appeared first on Myasthenia Gravis News.
** MGFA Disclaimer – Please read
Myasthenia Gravis Foundation of America (MGFA) and Bionews, Inc. (specifically Myasthenia Gravis News) have entered into a limited agreement that allows for the MGFA to post a link to Myasthenia Gravis News on the myasthenia.org website. Myasthenia Gravis News is a digital platform intended to provide the myasthenia gravis (MG) community with the most recent news and information on MG, as well as first-hand community perspectives from patient and caregiver columnists. All articles on Myasthenia Gravis News are original content produced by in-house writers and editors. Occasionally, Bionews seeks the opinion of outside experts for interviews and Q&As.
The publishing team at Myasthenia Gravis News is made up of science writers and editors, most of whom have PhDs in the life sciences; veteran journalists; and columnists who are members of the MG community. Together, they attempt to ensure that all content published on Myasthenia Gravis News is relevant, accurate, informative, relatable, and easy to understand.
Each piece of content is carefully selected and written by Bionews writers with the MG community in mind. Sources for news stories and resource pages include peer-reviewed studies, press releases, announcements, interviews, webinars, and conference sessions, among others. All articles go through a stringent fact-checking and editing procedure as part of Bionews’ process to ensure they are accurate, objective, comprehensive, and well-explained.
Columns are written by MG patients and caregivers who provide an intimate look at what it’s like to live with the disease. While columns are largely opinion and perspective pieces, each one still goes through a comprehensive editing and fact-checking process by Bionews editors to ensure clarity, accuracy, and fairness.
Myasthenia Gravis News’ site is strictly a news and information website about the disease. It DOES NOT provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a licensed physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The information provided is for educational purposes only and does not substitute for professional medical advice.
The content reflects the unique experiences of the authors and is not necessarily the opinion, views, or recommendations of the MGFA. Medical advisors and clinicians associated with or partnering with the MGFA do not peer review articles and information posted on the Myasthenia Gravis News platform or website. MGFA should not be liable for any information, opinions, articles, advice, guidance, or details posted on the Myasthenia Gravis News site. MGFA has posted this platform as a service to the MG community. Please consult with your doctor and healthcare professionals for specific recommendations and advice pertaining to your healthcare/treatment.